Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib versus standard EGFR-TKI first-line treatment in EGFR-mutated advanced or metastatic non-small cell lung cancer
2014-002694-11Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Standard of care EGFR-TKI (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-002694-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002694-11.